Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme

Abstract

The global burden of type 2 diabetes (T2D) is increasing, indicating an urgent need for improved disease prevention and management strategies. Contemporary, global, real‐world data, collected in a consistent way, on the characteristics, treatment and outcomes of people with T2D are lacking, particularly in low‐ and middle‐income countries where disease burden is increasing most rapidly. The DISCOVER study programme (http://clinicaltrials.gov identifiers: NCT02322762 and NCT02226822) is a global, prospective, 3‐year programme of observational research, which has been designed to fill this knowledge gap. DISCOVER is being conducted in 38 countries across six continents, including several lower‐middle‐ and upper‐middle‐income countries where patients have rarely or never been studied previously. In total, 15 992 people with T2D who had initiated a second‐line glucose‐lowering therapy have been recruited. Data being collected include information on demographics, clinical and treatment characteristics, socio‐economic status, clinical outcomes and patient‐reported outcomes. Findings from DISCOVER will provide unique insights into current patterns of T2D care worldwide, which should contribute to informing clinical guidelines and health policy, and may help to improve patient care.

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER

“…The DISCOVER study is a prospective, observational study of individuals with type 2 diabetes enrolled from 38 countries at initiation of second-line glucose-lowering medication [ 8 , 9 ]. Consecutive eligible adults were enrolled between December 2014 and June 2016 and followed at 6 months and 1, 2, and 3 years.…”

RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020

“…This might help in preparing informed clinical guidelines and prepare effective healthcare policies globally. [ 544 ]…”

Impact of micro‐ and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study

“…14 Between December 2014 and June 2016, consecutive eligible adults were enrolled from 38 countries (Supplemental Table S1) and followed at 6, 12, 24 and 36 months. 15 Patients were excluded who were pregnant, undergoing dialysis, had a history of renal transplant or were treated with an injectable agent or herbal remedy/natural medicine alone as a first-line agent. Patients from China (n = 1292) were excluded from this analysis due to regulations on data privacy released during the study.…”